Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies von Ludwig, H., Cohen, A. M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Günczler, P., Seewann, H. L., Schüller, J., Rhyner, K., Cavalli, F., Fritz, E.

Volltext

Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2 h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma von Fridrik, M.A, Jäger, G, Kienzer, H.R, Hausmaninger, H, Oppitz, P, Krieger, O, Zabernigg, A, Lang, A, Neubauer, M, Weidinger, G, Schiller, L, Seewann, H.L, Chott, A, Linkesch, W

Volltext

Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia von AGIS, H, WELTERMANN, A, MITTERBAUER, G, THALHAMMER, R, EDELHÄUSER, M, SEEWANN, H. L, VALENT, P, LECHNER, K, FONATSCH, C, GEISSLER, K

Volltext

A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML) von Kühr, T., Burgstaller, S., Apfelbeck, U., Linkesch, W., Seewann, H., Fridrik, M., Michlmayr, G., Krieger, O., Lutz, D., Lin, W., Pont, J., Köck, L., Abbrederis, K., Baldinger, C., Buder, R., Geissler, D., Hausmaninger, H., Lang, A., Zabernigg, A., Duba, C., Hilbe, W., Eisterer, W., Fiegl, M., Greil, R., Gastl, G., Thaler, J.

Volltext

Persisting Bone Marrow Aplasia Following Interferon-Alpha Combined with Ara-C for Chronic Myelogenous Leukemia von Fiegl, M., Chott, A., Seewann, H. L., Lechner, K., Gisslinger, H.

Volltext

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial von Fridrik, M A, Hausmaninger, H, Linkesch, W, Stöger, M, Sill, H, Neubauer, M, Seewann, H L, Klocker, J, Haidinger, R, Schiller, L, Pont, J, Raudaschl, G, Falk, M, Radaszkiewicz, T

Volltext

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease fragmin in unstabl... von KLEIN, W, BUCHWALD, A, HILLIS, S. E, MONRAD, S, SANZ, G, TURPIE, A. G. G, VAN DER MEER, J, OLAISSON, E, UNDELAND, S, LUDWIG, K

Volltext

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C von Hilbe, W, Kühr, T, Apfelbeck, U, Fridrik, M, Seewann, H, Stöger, M, Linkesch, W, Pont, J, Baldinger, C, Hartner, E, Bernhart, M, Geissler, D, Krieger, O, Lang, A, Lin, W, Ludwig, H, Duba, C, Greil, R, Gast, G, Thaler, J

Volltext

Heavy-chain immunoglobulin gene rearrangement and cytoplasmic immunoglobulin expression in acute monocytic leukemia following primary germ cell tumor von GREINIX, H. T, BEHAM-SCHMID, C, SILLY, H, HOEFLER, G, KASPAREK, A, SEEWANN, H. L

Volltext

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results von Ludwig, Heinz, Cohen, Amos M., Huber, Heinz, Nachbaur, David, Jungi, Walter F., Senn, Hansjörg, Günczler, Peter, Schüller, Johannes, Eckhardt, Sándor, Seewann, Heinz L., Cavalli, Franco, Fritz, Elke, Micksche, Michael

Volltext

Extramedullary haematopoiesis in the thyroid gland von SCHMID, Ch, BEHAM, A., SEEWANN, H. L.

Volltext

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia : long-term results of a multicenter phase-II study von THALER, J, GASTL, G, UTERMANN, G, KÜHR, T, AULITZKY, W, HUBER, C, FLUCKINGER, T, NIEDERWIESER, D, HUBER, H, SEEWANN, H, SILL, H, LANG, A, FALK, M, DUBA, C

Volltext

Non-systemic diffuse lymphangiomatosis of spleen and liver von SCHMID, C., BEHAM, A., URANÜS, S., MELZER, G., AUBÖCK, L., SEEWANN, H.L., KLIMPFINGER, M.

Volltext

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside von Thaler, J., Fluckinger, T., Huber, H., Lang, A., Abbrederis, C., Seewann, H., Silly, H., Baldinger, C., Duba, C., Huber, C., Niederwieser, D.

Volltext

Interferon-alpha-2 in the treatment of idiopathic myelofibrosis von Seewann, H. L., Gastl, G., Lang, A., Abbrederis, K., Thaler, J., Flener, R., Huber, Ch

Volltext

Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b von Seewann, Heinz L., Zikulnig, Ronald, Gallhofer, Gertraud, Schmid, Christine

Volltext

Chronic myeloid leukemia with a rare variant Philadelphia translocation: t(9;10;22)(q34;q22;q11) von Emberger, W, Behmel, A, Tschernigg, M, Seewann, H.L, Petek, E, Kroisel, P.M, Wagner, K

Volltext

Dose related effectiveness of alpha interferon in chronic myelogenous leukemia von Gastl, G., Aulitzky, Q., Tilg, H., Huber, H., Hausmaninger, H., Seewann, H. L., Coser, C., Prinoth, P., Huber, C.

Volltext

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas von Fridrik, M. A., Hausmaninger, H., Michlmayr, G., Haidinger, R., Seewann, H. L., Lehnert, M.

Volltext

Specific skin manifestations in acute leukemia with monocytic differentiation a morphologic and immunohistochemical study of 11 cases von Sepp, Norbert, Radaszkiewicz, Thaddäus, Meijer, Chris J. L. M., Smolle, Josef, Seewann, Helmut, Fritsch, Peter, Kerl, Helmut

Volltext